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Background: The prognosis for an abnormal medical finding is affected by both early detection and adherence to
the presecribed schedule for follow-up examinations. In this study, we examined the time to follow up after an
abnormal finding and determined the risk factors related to delays in follow up in a population-based screening
program.
Methods: The study population consisted of patients who were newly diagnosed with gastric cancer through a
gastric cancer screening program sponsored by the National Cancer Screening Program (NCSP) in 2005. Due to the
skewed nature of the distribution of time to follow up, medians and interquartile ranges (IQR) are presented, and
we analyzed the number of days preceding the follow-up time as a binary variable (≤90 days or >90 days). We
used logistic regression analyses to evaluate the risk factors for a long delay.
Results: The median number of days to follow-up initiation after an abnormal finding was 11 (IQR 7–27); 13.9% of
the patients with gastric cancer obtained their follow-up evaluation more than 90 days. Age, type of health
insurance, screening method, and screening results were risk factors for delays in follow up.
Conclusions: This study examined delays from the time of the discovery of an abnormal finding to time of the
follow-up evaluation. Because inadequate follow up of abnormal exam results undermines the potential benefits of
cancer screening, it is important to organize services that minimize delays between cancer screening and
treatment.
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Asian countries, including China, Japan, and Korea, have
the highest incidence of gastric cancer in the world [1,2].
Although the incidence of gastric cancer has declined in
Korea in recent decades, it remains the most common
cancer in this country. Because the prognosis for gastric
cancer is favorable when it is detected early, countries
with a high prevalence of this disease have sought to re-
duce the disease burden by providing gastric cancer
screening to average-risk populations [3]. In Korea, the
National Cancer Screening Program (NCSP), an orga-
nized cancer-screening service, recommends biennial
gastric cancer screening for males and females older* Correspondence: ecpark@yuhs.ac
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reproduction in any medium, provided the orthan 40 years of age via either upper gastrointestinal
series (UGIS) or endoscopy.
The prognosis for an abnormal medical finding is
affected by both early detection and adherence to the pre-
secribed schedule for follow-up examinations. Patient ad-
herence to follow-up recommendations is probably a
multifaceted phenomenon [4,5]. Previous research has
demonstrated that socioeconomic and demographic char-
acteristics and certain attitudes or misconceptions about
cancer are associated with delayed or incomplete follow
up. Such attitudes are common among low-income, mi-
nority, and underinsured or uninsured populations.
In countries with strong primary healthcare systems,
minimizing the time to diagnosis of cancer depends on
the ability and willingness of patients to present with po-
tential cancer symptoms and on those of primary care
practitioners to respond appropriately to those symp-
toms either by arranging for further investigation and/or. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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care system does not have strong gatekeeper system, and
the NCSP is not connected with systems that provide
further evaluation in the service of diagnosis or treat-
ment. The Korean government provides an opportunity
for the population to undergo gastric cancer screening
through the NCSP and provides a recommendation for
further follow-up evaluation if an abnormality is discov-
ered. Individuals with abnormal findings should then ar-
range to see a doctor or go to a hospital.
Traditionally, Korean cancer screening programs are
evaluated solely on the basis of screening rates. Informa-
tion about delays in diagnosis or treatment after an ab-
normal finding on gastric cancer screening tests is
scarce. Thus, in this study, we examined the time to fol-
low up after an abnormal finding and determined the
risk factors related to delays in follow-up evaluation in a
population-based screening program.
Methods
National cancer screening program
A nationwide gastric cancer screening program was
initiated in Korea in 1999 as part of the NCSP, which
recommends biennial gastric cancer screening for males
and females older than 40 years of age via either UGIS
or endoscopy performed at a clinic, hospital, or general
hospital designated as a gastric cancer screening unit by
the National Health Insurance Corporation (NHIC).
For those on Medical Aid and in the lower 50% of the
NHI premium scale, all such examinations are performed
free of charge. People on the upper 50% of the premium
scale paid 20% of the screening cost until 2008 and have
paid 10% of this cost since 2009. Screening results are no-
tified to all participants within 15 days by letter. Notifica-
tion process does not differ according to screening results
(normal, benign, suspicion of cancer, or cancer). Subjects
with findings indicating a suspicion of cancer or cancer
are referred for further evaluation or treatment. Partici-
pants with abnormal results voluntarily decide whether to
make an appointment for consultation with a doctor. Indi-
viduals who participate in the NCSP for gastric cancer
and are subsequently diagnosed with gastric cancer are
also supported financially by the Financial Aid Program
for cancer patients. The Financial Aid Program for Cancer
Patients was designed to relieve the financial burden of
cancer patients. Based on this program, patients suffering
from gastric cancers who participated in the NCSP as
people on the lower 50% of the premium scale and Med-
ical Aids recipients are financially supported with their
diagnosis and treatment. This program covers out of
pocket expenses for those medical costs [8].
The overall participation rates in the gastric cancer
screening were 17.9% in 2005 and 33.1% in 2008. The
positive rates for UGIS and endoscopy were 39.7 and 42.1per 1,000 screens. The cancer detection rates for UGIS
and endoscopy were 0.68 and 2.61 per 1,000 screens. The
sensitivities of UGIS and endoscopy for detecting gastric
cancer were 36.7 and 69.0%. The specificities of UGIS and
endoscopy were 96.1 and 96.0%, respectively [9,10].
Study population and data sources
We defined the study population as those who had parti-
cipated in gastric cancer screening through the NCSP in
2005 and who were newly diagnosed with gastric cancer.
The sample was selected using the database linking the
NCSP database with the Korea National Cancer Inci-
dence Database (KNCIDB). In total, 3083 individuals
with complete information were eligible. A total of 692
(28.9%) individuals with a previous diagnosis of gastric
cancer according to the KNCIDB were excluded. The
final sample consisted of 2,391 subjects.
We used data from the KNCIDB that was collected
within 1 year after the initiation of gastric cancer screen-
ing in 2005 to enable examination of the diagnostic work-
up of information obtained during the 12 months after
the first screening and to allow sufficient time for these
results to be fully reported. The KNCIDB is a nationwide,
hospital-based cancer registry and contains 95% of newly
diagnosed malignancies in Korea. We defined a cancer
diagnosis according to the criteria of the International
Classification of Diseases, code C16 (ICD-10:C16).
The NCSP database includes information on partici-
pants’ demographic characteristics, screening date, and
screening results. Subjects whose tests were completed
were sent a letter that defined the result as “normal,” “be-
nign,” “suspicious,” or “cancer.” We defined results desig-
nated as suspicious or indicative of cancer as positive with
respect to both UGIS and endoscopy.
We defined the time to follow up as the period from
the date of gastric cancer screening to the date of the
initiation of follow-up. The date of the initiation of
follow-up was defined as the first date when individuals
with positive results had consulted with a doctor for
their further evaluation and treatment. We analyzed the
time to follow up through the linkage between the NCSP
data and the data about medical claims obtained from
the National Health Insurance Corporation (NHIC).
Delays were calculated as number of days. A classifica-
tion of a long (>90 days ) delay was chosen as the
threshold for a follow-up delay. This has been used by
other studies, and it is generally assumed that a 3-month
delay is too long [6,11-13]. This study was approved by
the Institutional Review Board of the National Cancer
Center of Korea.
Data analysis
Our primary outcome was the median number of
days from the date of gastric cancer screening to the
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nature of the data on number of days to follow-up,
medians and interquartile ranges (IQR) are presented.
We analyzed follow-up days as a binary variable
(≤90 days or >90 days) and used the χ2 test to
analyze group differences in the frequencies of cat-
egorical variables.
We used logistic regression analyses to evaluate the
risk factors for a long delay and included covariates
in multivariate analyses. The variables included age,
sex, health insurance status as a proxy income indica-
tor, gastric cancer screening method (UGIS, endos-
copy), gastric cancer-related “alarm” symptoms (e.g.,
fatigue, abdominal pain, and discomfort, abdominal
bloating, indigestion, changes in bowel habits, and
weight loss). The SAS software package (ver. 9.1; SAS
Institute Inc., Cary, NC, USA) was used for all statis-
tical calculations.Table 1 Distribution of median days to follow-up
Variables
Total
Age 40–49
50–59
60–69
70+
Sex Male
Female
Result Suspicion of cancer
Cancer
Health Insurance Medical Aid
NHI premium in the lower50%
NHI premium in the upper50%
Method UGIS
EGD
Symptom
Fatigue No
Yes
Abdominal pain and discomfort No
Yes
Abdominal bloating No
Yes
Indigestion No
Yes
Changes in bowel habits No
Yes
Weight loss No
YesResults
Baseline characteristics of study population
A total of 2,391 individuals who had participated in the
NCSP in 2005 were newly diagnosed with gastric cancer
(Table 1). Of these, 668 (27.9%) obtained suspicious
results, and 1723 (72.1%) were diagnosed with gastric can-
cer. Of the participants, 401 (16.8%) underwent UGIS and
1990 (83.2%) underwent EGD. The sample included 1641
(68.6%) males and 750 (31.4%) females.
Time to follow-up after an abnormal finding
The median number of days to initiating follow-up after
an abnormal finding was 11 (IQR 7-27; Table 1). The
median number of days for gastric cancer patients with
Medical Aid was 22 (IQR 135–6), compared with 10 days
for individuals with NHI in the lower 50% premium
scale and 12 days for individuals in the NHI upper 50%
premium. The median number of days to follow up wasNumber (%) Median days IQR
2391 (100.0) 11 27-7
360 (15.1) 9 16-6
607 (25.4) 11 23-7
943 (39.4) 12 28-7
481 (20.1) 15 48-7
1641 (68.6) 12 27-7
750 (31.4) 11 28-6
668 (27.9) 42.5 308-15
1723 (72.1) 9 15-6
145 (6.1) 22 135-6
954 (39.9) 10 21-6
1292 (54.0) 12 30-7
401 (16.8) 46 302-18
1990 (83.2) 10 19-6
1981 (82.9) 11 27-7
410 (17.1) 12 28-7
1712 (71.6) 12 31-7
679 (28.4) 10 20-6
2083 (87.1) 11 28-7
308 (12.9) 11 22.5-6
2104 (88.0) 11 28-7
287 (12.0) 11 25-6
2094 (87.6) 11 27-7
297 (12.4) 13 28-7
2283 (95.5) 12 28-7
108 (4.5) 10 18.5-6
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42.5 days for those with suspicious results. The upper
IQR among those with suspicious results was 308 days,
indicating that 25% of patients did not obtain a follow-
up medical evaluation for at least 308 days. Similarly,
one-quarter of patients with gastric cancer who were
diagnosed via UGIS initiated follow up after 302 days.
According to the results, 59.4% of patients with a sus-
picious finding from the screening began follow up
within 90 days, whereas 96.5% with results indicative of
cancer sought follow up within this time frame (Table 2).
Patients with gastric cancer who were in their 40s began
follow-up within 90 days, compared with 79.2% of those
aged 70 or older. Cancer patients with Medical Aid were
more likely to have a long delay before follow up than
were those with NHI.Table 2 Comparison of study population by follow-up period
Variables
Total
Age 40–49
50–59
60–69
70+
Sex Male
Female
Result Suspicion of cancer
Cancer
Health Insurance Medical Aids
NHI premium in the lower 50%
NHI premium in the upper 50%
Method UGIS
EGD
Symptom
Fatigue No
Yes
Abdominal pain and discomfort No
Yes
Abdominal bloating No
Yes
Indigestion No
Yes
Changes in bowel habits No
Yes
Weight loss No
YesMultivariate analysis
According to the multivariate model, age, screening
results, screening methods, health-insurance status,
and symptoms of indigestion were associated with
follow-up interval (Table 3). Older people had a 0.977
odds ratio (OR) of a follow-up time within 90 days.
Participants with screening results indicative of cancer
had about a 15 times higher probability of seeking
follow up within 90 days than did those with suspi-
cious results. Participants who were screened via en-
doscopy had about a 1.5 times higher probability of
follow up within 90 days compared with those who
underwent UGIS. Participants with symptoms of indi-
gestion had about a 1.6 times higher probability of
follow up within 90 days than did those without these
symptoms.Follow-up time
<90 days
Follow-up time
≥90 days
Number (%) P-value
2059 (86.1) 332 (13.9)
328 (91.1) 32 (8.9) <0.0001
544 (89.6) 63 (10.4)
806 (85.5) 137 (14.5)
381 (79.2) 100 (20.8)
1418 (86.4) 223 (13.6) 0.5356
641 (85.5) 109 (14.5)
397 (59.4) 271 (40.6) <0.0001
1662 (96.5) 61 (3.5)
103 (71.0) 42 (29.0) <0.0001
860 (90.2) 94 (9.9)
1096 (84.8) 196 (15.2)
235 (58.6) 166 (41.4) <0.0001
1824 (91.7) 166 (8.3)
1708 (86.2) 273 (13.8) 0.7454
351 (85.6) 59 (14.4)
1449 (84.6) 263 (15.4) 0.0009
610 (89.8) 69 (10.2)
1783 (85.6) 300 (14.4) 0.0573
276 (89.6) 32 (10.4)
1807 (85.9) 297 (14.1) 0.3774
252 (87.8) 35 (12.2)
1805 (86.2) 289 (13.8) 0.7523
254 (85.5) 43 (14.5)
1966 (86.1) 317 (13.9) 0.9991
93 (86.1) 15 (13.9)
Table 3 Risk factors for delay in follow up after abnormal
findings in gastric cancer screening
Variables OR Upper CI Lower CI
Age 0.977 0.962 0.991
Sex
Male 1.000
Female 0.847 0.630 1.138
Result
Suspicion of cancer 1.000
Cancer 14.902 10.606 20.937
Health Insurance
Medical Aid 1.000
NHI premium in the lower 50% 2.471 1.368 4.461
NHI premium in the upper 50% 1.516 0.935 2.459
Method
UGIS 1.000
Endoscopy 1.481 1.075 2.041
Symptom
Fatigue
No 1.000
Yes 0.900 0.611 1.323
Abdominal pain and discomfort
No 1.000
Yes 0.919 0.594 1.423
Abdominal bloating
No 1.000
Yes 1.413 0.870 2.295
Indigestion
No 1.000
Yes 1.607 1.011 2.555
Changes in bowel habits
No 1.000
Yes 1.050 0.681 1.618
Weight loss
No 1.000
Yes 0.742 0.377 1.462
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In this study, we observed that 13.9% of patients with gas-
tric cancer obtained follow-up evaluation more than
90 days, even though they were told that they needed
medical services for diagnostic confirmation and treat-
ment because their screening results were suspicious for
cancer or indicated cancer. Age, health-insurance type,
screening method, and screening results were risk factors
for follow-up delay. Specifically, the 90-day follow-up rate
was lower among individuals over 70 years of age, recipi-
ents of Medical Aid, individuals with a suspicious results,and those who underwent UGIS compared with indivi-
duals who were younger, NHI beneficiaries, individuals
with results indicative of cancer, and those who underwent
endoscopy, respectively.
These results are consistent with reports from previ-
ous studies that cancer screening follow-up delay varies
by age and income [4,14-17]. The follow-up delay
among individuals aged 70 or over may be due to re-
luctance to follow the physician’s recommendation to
seek diagnostic confirmation or treatment. It may also
be more difficult for elderly individuals to understand
the need for follow up or to follow up within an ap-
propriate period of time. In the current study, Medical
Aid recipients were also less likely than NHI beneficiar-
ies to have an appropriate follow-up period, even
though recipients of Medical Aid who participated in
the NCSP for gastric cancer and was subsequently
diagnosed with gastric cancer through the program
would be supported financially through the Financial
Aid Program. This indicates financial or other barriers
may affect recipients of Medical Aid despite free-of-
charge cancer screening and the Financial Aid Program
for treatment. These people may be dealing with other
issues, including difficulty in accessing facilities and
multiple personal and cultural barriers to choosing to
undergo follow-up evaluations [18]. Participants who
underwent endoscopy may have responded more rap-
idly to abnormal results because they believed endos-
copy to be more accurate than UGIS in detecting
gastric cancer [18].
The literature contains no consensus about the defin-
ition of a “reasonable” follow-up interval after an abnor-
mal screening result for gastric cancer. Some investigators
have found that follow-up intervals of up to 3 months
may not impact overall survival from breast or colorectal
cancer, whereas others have shown that women who
waited more than 30 days for evaluation after the detec-
tion of breast cancer were more likely to experience can-
cer recurrence or death [4,14,19]. The general perception
among patients, health professionals, and politicians is
that delay has a definitely unfavorable effect on outcome
[7,11,12,20-22].
The cancer-care-continuum disparities model begins
with prevention and early detection and continues
through the survival period. Several of the factors that
may contribute to cancer disparities may occur at each
end of the continuum or at the stages in between, such as
diagnosis and treatment [14,18,23,24]. This study was un-
able to address the long-term clinical significance of the
delay in follow up after an abnormal gastric cancer screen-
ing result; however, similar differences at other points
along the cancer-care continuum may have a cumulative
clinically significant overall impact on mortality. Inad-
equate follow up of abnormal exam results undermines
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nized cancer screening program is one of many interven-
tions for reducing disparities in the cancer-care
continuum. Services from cancer screening to treatment
need to be organized so that delays are minimized.
Improvements in the diagnostic and treatment process
should be achievable, particularly for those whose delays
were longest. The design of tailored and targeted interven-
tions such as campaigns directed at specific age groups
and social classes may help to reduce these delays. Inter-
ventions should involve the local community and should
be related to each aspect of the aforementioned barriers
that may contribute to delays in follow-up.
Several European countries with strong primary
healthcare systems, such as the United Kingdom and
Denmark, have developed organized cancer screening
systems to reduce the time for the diagnosis and treat-
ment of cancer. National fast-track referral guidance has
also recently been introduced. Suspicion of cancer leads
to prompt referral of the patient to a specialist for as-
sessment and initiation of a progressive diagnostic pro-
gram that is conducted within a limited time frame [11].
In the context of a gastric cancer screening unit, the
absence of the sort of close relationship or continuous
connection that exists between primary physicians and
patients may have affected the long follow-up periods
found by the current study. The use of primary-
physician-based intervention may be a good way to de-
crease the follow-up time. Additionally, the Public
Health Centers in Korea are now primarily responsible
for encouraging target individuals to participate in the
NCSP. The Public Health Centers need to encourage the
public, via telephone or letter, not only to participate,
but also to follow up and maintain an appropriate
follow-up timeline after an abnormal finding by cam-
paigning. The NCSP needs to develop a quality improve-
ment (QI) infrastructure to implement an effective
strategy for improving follow up [26].
Follow-up delay may be affected by knowledge of a
malignancy, perceptions of the results as reported in the
letter, or access to services [6,7]. Sensitive and specific
strategies to reduce patient delays, especially those
related to knowledge of a malignancy or perceptions of
the letter reporting the screening results, should improve
awareness of cancer and aid in patients’ interpretation of
screening results. Delays may be reduced by crafting let-
ters that present the results in a way that is easily under-
stood by underprivileged participants according to age,
education, and income; that provides clear referral guid-
ance or a referral protocol; or that enables access to a
well-organized system that facilitates prompt action by
participants with abnormal findings.
This study has several limitations. First, we did not
have information about beliefs about screening, healthliteracy, patient–provider communication and relation-
ships, or system failures. It would be useful to collect
such information in future studies to enable a more
comprehensive analysis of our findings. Second, we had
no information about participants who did not use med-
ical services at all. Work is needed to further explore the
reasons that patients do not see a doctor at all and to
examine the implications of this behavior. Finally, infor-
mation about stage distribution was not available. It
would be informative to compare stage distribution be-
tween those who had follow-up delay or not.
Some recent studies in Korea have focused on partici-
pation in cancer screening programs, especially orga-
nized cancer screening programs [27-33]. One study
suggested that progress had been made toward bridging
disparities in organized screening for gastric cancer that
were related to socioeconomic status [34]. However, pol-
icy makers have paid little attention to delays or varia-
tions in the initiation and completion of treatment until
now. This study provides additional evidence of follow-
up delay and variations in the time to follow up after an
abnormal finding. This information may be used in sub-
sequent analyses to identify barriers that lead to differ-
ences in the lengths of such delays. Interventions can
then be implemented to address delays between the
diagnosis and treatment of gastric cancer.
Conclusions
This study provides additional evidence of follow-up
delay and variations in the time to follow up after an ab-
normal finding. An organized cancer screening program
is one of many interventions for reducing disparities in
the cancer-care continuum. Inadequate follow up of ab-
normal exam results undermines the potential benefits
of cancer screening. Therefore, it is important to
organize services that minimize delays and decrease var-
iations in the time between cancer screening and
treatment.
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